The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management ...
SurvivorNet on MSN
Could timing give your cancer treatment a boost? New study on the best time to receive immunotherapy & chemo for non-small cell lung cancer
A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...
MedPage Today on MSN
Time of Day Matters for Immunochemotherapy in Lung Cancer
This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...
The FDA has granted regenerative medicine advanced therapy (RMAT) designation to KB707 for the treatment of advanced or metastatic NSCLC. 1 KB707 is an inhaled, re-dosable immunotherapy designed to ...
Reducing pembrolizumab infusions from 30 minutes to 10 minutes could be a safe alternative for patients and open hundreds of ...
The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...
Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related ...
A curious phenomenon seen by oncologists, that morning patients do better than those receiving afternoon infusions, gains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results